Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Blood Test Shows Statistically Significant Association With Alzheimer's Disease (AD), May Predict Conversion Of Mild Cognitive Impairment To AD
Dr. Zsuzsanna Nagy of the University of Birmingham presented data from a clinical study, funded by Cytox Limited, demonstrating that a simple blood-based biomarker discriminated between patients with Alzheimer"s disease (AD) and control subjects. The findings were statistically highly significant, and the test discriminated between the two groups with 80% sensitivity and 80% specificity. The results also showed that 40% of the mild cognitive impairment (MCI) patients tested had the same test results as AD patients. Follow up study of MCI patients enrolled in an earlier study found that the test allowed early identification of those MCI patients who later developed dementia. The results were presented at the 2009 Alzheimer"s Association International Conference on Alzheimer"s Disease (ICAD 2009), held in Vienna, Austria.

Senate Finance Committee Under Pressure To Produce Health Bill
President Obama told Sen. Max Baucus that he wants a Senate Finance Committee health overhaul bill by the end of the week, The Associated Press reports. "These officials said Obama made his wishes known directly to Baucus, D-Mont., at a White House meeting Monday attended by administration officials and senior Democratic lawmakers."
News of the day
200 Percent Increase In Cardiovascular Medication In Canada
A new study in the Canadian Medical Association Journal (CMAJ) reports that the number of prescriptions in Canada for cardiovascular medications has been increasing over the last ten years. There has been a 200 percent increase in costs. Overall costs of cardiovascular medications exceeded $5 billion in 2006. And statins accounted for nearly 40 percent of the expenditure.
Public Health

Fanconi Anemia: Genetically Corrected Blood Cells Obtained From Patients' Skin Cells

Collaboration research carried out by the teams of Jordi Surrallés, Universitat Autònoma de Barcelona (UAB); Juan Carlos IzpisÃôa-Belmonte and Angel Raya, Centre for Regenerative Medicine of Barcelona (CMRB); and Juan Antonio Bueren, Centre for Energetic, Environmental and Technological Research (CIEMAT), has resulted in the generation of blood cells from skin cells of patients with a genetic disease known as Fanconi anemia. The process is based on gene therapy and cell reprogramming techniques in which cells similar to embryonic stem cells known as induced pluripotent stem (iPS) cells can be generated. The research article was published in this week"s digital version of Nature. The research demonstrates that, for the first time, in the case of a genetic disease such as Fanconi anemia it is possible to correct the genetic defect in patient-specific skin cells by converting them into cells similar to embryonic stem cells (iPS cells) which later can be differentiated towards blood cells. These results are the proof of concept that this new therapeutic strategy has the potential of generating tissues using the very skin of those affected with these genetic diseases. This observation is particularly important in diseases such as Fanconi anemia, where one of the main problems lies in the lack of blood cell in the bone marrow of those affected. However, according to researchers, this new therapeutic strategy can be applied to many other genetic diseases by differentiating iPS cells towards healthy tissues these patients lack. The generation of blood cells in this research was carried out in vitro, in cell culture plates, which places the research in a preclinical environment. It remains unknown whether they would generate blood cells after being transplanted. Moreover, the transplant of embryonic stem cells in animals has revealed that these cells can cause tumours. Therefore, the possibility of treating Fanconi anemia patients by transplanting iPS cells must wait until the efficacy and safety of these new discoveries are demonstrated in experimental models. Researchers taking part in the study are confident that in the next few years it will be possible to improve the efficacy and safety of this new scientific discovery, and that some time in the future, clinical professionals will be able to cure patients suffering from genetic diseases such as Fanconi anemia. UAB and CIEMAT, leading research centres in Fanconi anemia Fanconi anemia is a rare hereditary disease which mainly affects the bone marrow and causes it to produce less blood cells. The lack of white blood cells makes individuals more vulnerable to infections, while the lack of platelets or red blood cells may prevent clotting or lead to fatigue. Treatment includes transplanting healthy blood stem cells from the bone marrow or umbilical cord of a compatible donor or, if possible, a relative. Unfortunately, few patients can find a healthy and compatible donor. UAB, through the Research Group directed by Dr Jordi Surrallés, professor at the Department of Genetics and Microbiology, and CIEMAT, through the group led by Dr Juan Antonio Bueren, director of the Hematopoiesis and Gene Therapy Division, are two of the world"s leading centres in the research on Fanconi anemia. In recent years they have made many important contributions to help understand the genetic mechanisms of the disease. These past few years, the Office of the Vice-Rector for Strategic Projects at UAB has cofinanced translational research on Fanconi anemia as a model disease in biomedical and biotechnological research. Maria Jesus Delgado Universitat Autonoma de Barcelona


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009